Profile data is unavailable for this security.
About the company
Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
- Revenue in AUD (TTM)86.39k
- Net income in AUD-2.49m
- Incorporated2005
- Employees--
- LocationVectus Biosystems Ltd3-11 Primrose Avenue,ROSEBERY 2018AustraliaAUS
- Phone+61 29381-1000
- Fax+61 29662-1720
- Websitehttps://www.vectusbiosystems.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wellfully Ltd | 1.31m | -1.34m | 1.48m | 36.00 | -- | -- | -- | 1.13 | -0.003 | -0.003 | 0.0034 | -0.0034 | 0.377 | 0.3166 | 1.57 | -- | -38.36 | -175.88 | -- | -441.84 | 48.61 | -- | -101.74 | -266.08 | 0.2159 | -- | -- | -- | -42.78 | -5.87 | 12.98 | -- | 21.75 | -- |
| Cambium Bio Ltd | 128.99k | -2.26m | 3.94m | -- | -- | 1.42 | -- | 30.52 | -0.4599 | -0.4599 | 0.0173 | 0.2327 | 0.0318 | -- | 1.00 | -- | -55.60 | -30.97 | -144.62 | -99.20 | 62.39 | -- | -1,748.79 | -74.07 | -- | -149.70 | 0.1443 | -- | -- | -- | -33.72 | -- | -- | -- |
| Vectus Biosystems Ltd | 86.39k | -2.49m | 4.26m | -- | -- | 1.80 | -- | 49.27 | -0.0467 | -0.0467 | 0.0016 | 0.0445 | 0.0191 | -- | -- | -- | -54.95 | -96.22 | -68.14 | -691.17 | -- | -- | -2,880.80 | -27,693.78 | -- | -439.76 | 0.00 | -- | 69,287.50 | 97.87 | 13.64 | -- | -- | -- |
| Invex Therapeutics Ltd | 1.70m | -1.64m | 5.64m | -- | -- | 0.9909 | -- | 3.31 | -0.0218 | -0.0218 | 0.0227 | 0.0757 | 0.1178 | -- | 7.95 | -- | -11.35 | -15.73 | -12.20 | -16.55 | -- | -- | -96.35 | -535.37 | -- | -- | 0.00 | -- | 35.66 | 566.05 | 78.81 | -- | -- | -- |
| Neuroscientific Biopharmaceuticals Ltd | 2.39m | 324.21k | 5.64m | -- | 17.18 | 1.05 | 13.57 | 2.36 | 0.0023 | 0.0023 | 0.0165 | 0.037 | 0.4458 | -- | 48.82 | -- | 6.04 | -46.72 | 6.46 | -51.16 | -- | -- | 13.56 | -199.33 | -- | 33.42 | 0.00 | -- | -52.76 | 82.13 | 130.34 | -- | -37.50 | -- |
| Holista Colltech Limited | 5.46m | -4.64m | 6.13m | 3.00 | -- | -- | -- | 1.12 | -0.0166 | -0.0166 | 0.0196 | -0.0094 | 1.48 | 3.54 | 5.39 | -- | -125.43 | -42.59 | -1,528.79 | -63.58 | 51.69 | 56.37 | -85.04 | -39.27 | 0.2094 | -282.55 | -- | -- | -27.82 | -5.65 | -230.77 | -- | -37.12 | -- |
| Avecho Biotechnology Ltd | 339.30k | -3.48m | 6.34m | 29.00 | -- | 1.50 | -- | 18.68 | -0.0012 | -0.0012 | 0.0001 | 0.0013 | 0.0693 | 4.26 | 0.7043 | -- | -71.20 | -47.08 | -105.46 | -55.25 | -45.60 | 78.67 | -1,026.91 | -156.43 | 3.48 | -- | 0.0316 | -- | -58.07 | -19.42 | -46.71 | -- | -- | -- |
| Zelira Therapeutics Ltd | 1.02m | -36.57m | 7.72m | 8.00 | -- | -- | -- | 7.54 | -3.22 | -3.22 | 0.0902 | -0.3979 | 0.0524 | 0.0609 | 5.06 | -- | -188.05 | -46.98 | -246.20 | -50.16 | 91.73 | -- | -3,587.90 | -1,063.82 | 0.424 | -6.78 | 3.35 | -- | -82.72 | -35.59 | -556.18 | -- | -- | -- |
| Island Pharmaceuticals Ltd | 4.72k | -2.86m | 9.90m | -- | -- | 6.51 | -- | 2,096.89 | -0.0318 | -0.0318 | 0.00005 | 0.012 | 0.002 | -- | 0.0104 | -- | -124.17 | -- | -173.37 | -- | -- | -- | -60,684.75 | -- | -- | -544.58 | 0.2174 | -- | -57.45 | -- | -1.20 | -- | -- | -- |
